BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on darunavir/cobicistat: increased risk of therapeutic failure and mother-to-child transmission of HIV

Active substance: darunavir, cobicistat

The company Janssen-Cilag GmbH is circulating information on the fact that treatment with darunavir/cobicistat should not be initiated during pregnancy.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 588KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK